SCHEDULE: BlackRock Discloses 5.7% Passive Stake in Tonix Pharmaceuticals

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.7% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp.'s common stock as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 420,448 shares of Tonix Pharmaceuticals Holding Corp. Common Stock.
• This aggregate amount represents 5.7% of the class of securities.
• BlackRock, Inc. holds sole voting power over 411,151 shares.
• BlackRock, Inc. holds sole dispositive power over 420,448 shares.
• No shared voting or dispositive power was reported.
• The filing was made by BlackRock, Inc. as a parent holding company or control person.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment as it does not contain performance data, strategic updates, or forward-looking statements that would typically influence sentiment.

Future Outlook

NA

Industry Context

This Schedule 13G filing is a standard disclosure by a large institutional investor, BlackRock, Inc., indicating its passive ownership stake in Tonix Pharmaceuticals Holding Corp. Such filings are routine for investment managers that cross a 5% beneficial ownership threshold in a public company, demonstrating compliance with SEC reporting requirements for significant shareholders.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can be viewed as a vote of confidence or a passive investment.

Key Dates

Keywords

BlackRock, Tonix Pharmaceuticals Holding Corp., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing